Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced its financial results for the Second quarter (Q2FY25) ended on September 30th, 2024. Financial Highlights Q2 FY25 (July 2024 to September 2024) • Consolidated revenue increased 2% year-over-year to INR 14,058 million. • Consolidated EBITDA decreased
Revenue from operations increased sequentially by 13% to Rs. 891 crores, down 2% year-on-year First half FY25 revenue was broadly flat, in line with our guidance, at Rs. 1,681 crores Syngene International Limited today announced its second quarter and half year financial results. Revenue from
OneSource Specialty Pharma, a newly formed CDMO, is formed from the merger of three CDMO businesses within the Strides Group, which boasts a 30-year track-record of excellence in manufacturing and quality. The company is launching its new brand identity with a strong emphasis on customer
Expands high entry barrier portfolio; Leadership in Women’s Health (#1 in Gynae IPM[i]) High entry barrier portfolio with specialty R&D tech platforms across - Recombinants, Niche Biologics, Novel Delivery and Immunoglobulins Only innovator in the world to develop patented recombinant Anti-D Brands across Women’s Health
FY2024 Performance Highlights Highest ever full-year Revenue of ₹40,555 million in FY24, up 14.4% YoY Highest ever full-year EBITDA of ₹7,477 million in FY24, up 77.6% YoY US business achieved top end of $250 million revenue outlook for FY24, grew by 11.8% YoY Net
Full-year revenue from operations up 9% to Rs 3,489 Cr, PAT1 up 12% to Rs 519 Cr Fourth quarter revenue from operations declined 8% year-on-year to Rs. 917 Cr, PAT1 increased 6% to Rs. 189 Cr Syngene International Limited today announced its full-year
In a significant stride towards enhancing global health security and pandemic preparedness, TechInvention Lifecare Pvt. Ltd. is proud to announce the ground breaking of its Global Collaborative Centre for Medical Countermeasures (GCMC) with an investment of approx. USD 15 million. The centre is strategically located
Company reports resilient performance in the nine months to date: revenue from operations up 17% to Rs 2,572 crores, PAT up 16% to Rs 330 crores (before exceptional items) Syngene International Limited today announced its third quarter financial results. Reported revenue from operations for the quarter
Revenue from operations up 18.5% to Rs 910 crores, PAT (before exceptional items) up 20% to Rs 122 crores First half FY24 revenue from operations was up 22% to Rs 1,718 crores; Profit after tax (before exceptional items) up 23% to Rs 215 crores Syngene International Limited
MGM Cancer Institute, a state-of-the art hospital at the forefront of cancer care, today organised a cadaveric-workshop on implant-based breast reconstruction. This procedure specific workshop, designed exclusively for the surgical fraternity, focused on advanced techniques in implant-based breast reconstruction, enriching the knowledge and skills of
